AZAngela Zedda

Angela Zedda

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Angela Zedda has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Left Atrial Isolation and Appendage Occlusion in Patients With Atrial Fibrillation at End-Stage Left Atrial Fibrotic Disease

    by Angela Zedda, Yan Huo, Mads Kronborg, Stefan Ulbrich, Julia Mayer, Liying Pu, Utz Richter, Thomas Gaspar, Judith Piorkowski, Christopher Piorkowski

    Background: Atrial fibrillation (AF) ablation in an end-stage left atrial (LA) fibrotic disease is more complex, has more recurrences, and may compromise transport function and stroke risk. We explored whether a total left atrial isolation procedure (TLAI) followed by left atrial appendage occlusion is a feasible treatment concept for rhythm and stroke risk control. Methods: Patients with symptomatic AF with extended LA fibrosis were enrolled consecutively for TLAI followed by left atrial appendage occlusion. At enrollment, all patients received a sinus rhythm LA voltage map. For TLAI, LA anterior and paraseptal ablation lines were placed, combined with right atrial and epicardial line completion and right pulmonary vein isolation as needed. Rhythm follow-up was provided through continuous monitoring using implantable cardiac devices. Results: Ninety-two patients (71±9 years, 41% male, 84% persistent AF, CHA 2 DS 2 -VASc 4) underwent 104 ablation procedures. Follow-up duration measured 48±22 months. At 12-month follow-up 70 out of 92 (76%) patients were free from any atrial arrhythmia recurrence, off antiarrhythmic drugs. All intended left atrial appendage occlusion procedures were successfully performed 6 to 8 weeks after TLAI. Combination of TLAI and left atrial appendage occlusion attenuated the native 4% annual stroke risk to <1% over the entire course of the study. Patients’ clinical AF and heart failure symptoms (European Heart Rhythm Association and New York Heart Association classification) significantly improved and remained stable during further follow-up. Invasive hemodynamic assessment as well as echocardiographic transport function analysis did not show evidence of detrimental hemodynamic effects of the treatment concept. Conclusions: This is the first report on a structured concept of interventional electrical LA isolation and LA appendage occlusion for rhythm and stroke risk control in patients with AF at an end-stage left atrial fibrotic disease. We report feasibility, safety, and efficacy of such a treatment approach.


  • Left atrial fibrosis predicts left ventricular ejection fraction response after atrial fibrillation ablation in heart failure patients: the Fibrosis-HF Study

    by Bettina Kirstein, Sebastian Neudeck, Thomas Gaspar, Judith Piorkowski, Simon Wechselberger, Mads Brix Kronborg, Angela Zedda, Anastasia Hankel, Ali El-Armouche, Jakub Tomala, et al.

    Aims: Atrial fibrillation (AF) and heart failure (HF) often coexist. Catheter ablation has been reported to restore left ventricular (LV) function but patients benefit differently. This study investigated the correlation between left atrial (LA) fibrosis extent and LV ejection fraction (LVEF) recovery after AF ablation. Methods and results: In this study, 103 patients [64 years, 69% men, 79% persistent AF, LVEF 33% interquartile range (IQR) (25–38)] undergoing first time AF ablation were investigated. Identification of LA fibrosis and selection of ablation strategy were based on sinus rhythm voltage mapping. Continuous rhythm monitoring was used to assess ablation success. Improvement in post-ablation LVEF was measured as primary study endpoint. An absolute increase in post-ablation LVEF ≥10% was defined as ‘Super Response’. Left atrial fibrosis was present in 38% of patients. After ablation LVEF increased by absolute 15% (IQR 6–25) (P < 0.001). Left ventricular ejection fraction improvement was higher in patients without LA fibrosis [15% (IQR 10–25) vs. 10% (IQR 0–20), P < 0.001]. An inverse correlation between LVEF improvement and the extent of LA fibrosis was found (R2 = 0.931). In multivariate analysis, the presence of LA fibrosis was the only independent predictor for failing LVEF improvement [odds ratio 7.2 (95% confidence interval 2.2–23.4), P < 0.001]. Echocardiographic ‘Super Response’ was observed in 55/64 (86%) patients without and 21/39 (54%) patients with LA fibrosis, respectively (P < 0.001). Conclusion: Presence and extent of LA fibrosis predict LVEF response in HF patients undergoing AF ablation. The assessment of LA fibrosis may impact prognostic stratification and clinical management in HF patients with AF.